Stockreport

BioCryst Announces FDA Approval of ORLADEYO® (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to <12 Years [Yahoo! Finance]

BioCryst Pharmaceuticals, Inc.  (BCRX) 
Last biocryst pharmaceuticals, inc. earnings: 3/5 07:05 am Check Earnings Report
US:NASDAQ Investor Relations: biocryst.gcs-web.com/investor-relations
PDF -Oral pellet formulation provides child-friendly method of administration- –Showed early and sustained reductions in monthly attack rates in APeX-P– RESEARCH TRIANG [Read more]